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The metabotropic glutamate receptor 5 (mGluR5) is a high-interest
target for PET imaging because it plays a role in several patholo-
gies, including addiction, schizophrenia, and fragile X syndrome.
Methods: We studied the pharmacokinetics of 18F-FPEB (3-18F-
fluoro-5-(2-pyridinylethynyl)benzonitrile), a selective PET radioligand
for mGluR5, and used it to quantify mGluR5 in rat brain. Quantifica-
tion was performed using both arterial sampling in combination with
compartment models and simplified reference methods. The simpli-
fied reference tissue model (SRTM), Ichise’s original multi-linear ref-
erence tissue model (MRTMO), and Logan noninvasive were tested
as reference models with nondisplaceable binding (BPND) as outcome
parameter. Additionally, test–retest scans were obtained in 6 animals.
Results: 18F-FPEB uptake in rat brain was consistent with its known
distribution. No radiometabolites were present in the brain, and binding
was specific as shown in blocking experiments, which also confirmed
the cerebellum as a viable reference region. A 2-tissue-compartment
model was used to determine BPND for the striatum (11.7 ± 1.5), nu-
cleus accumbens (10.6 ± 2.0), hippocampus (9.0 ± 1.2), cortex (7.2 ±
1.0), and thalamus (4.0 ± 0.9). Reference methods were able to esti-
mate these values with small bias (,2%). Test–retest analysis showed
high repeatability between scans below 6%, also for shorter scan
durations of 30 and 60 min. Conclusion: Because of its favorable
reversible kinetics, high specificity, and absence of brain radiometa-
bolites 18F-FPEB proves a highly useful tracer for in vivo visualization
of the mGluR5 in rat brain. Moreover, reference tissue models allow
noninvasive, rapid scanning with good test–retest.
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The metabotropic glutamate receptor type 5 (mGluR5) is a
postsynaptic G-protein–coupled glutamate receptor predominantly
located extrasynaptically (1). Contrary to the rapid fluctuations
of glutamate levels inside the synapse, extrasynaptic levels have
slower temporal dynamics allowing for longer-lasting changes in
activity states of both glial and neuronal cells (2). The mGluR5
has been implicated in several psychiatric and genetic disorders,
such as schizophrenia, fragile X syndrome, and addiction (3).
The first tracer suitable for both preclinical and clinical use,
11C-ABP688, was developed by Ametamey et al. in 2006 (4). Despite its
favorable characteristics, the major limitation of 11C-ABP688 remains
the short half-life of its radioisotope. Acknowledging this situation, Wong
et al. optimized the cumbersome and low productive radiosynthesis of
18F-FPEB (3-18F-fluoro-5-(2-pyridinylethynyl)benzonitrile) by sim-
plifying the process and increasing the radioactive yield. They ad-
ditionally performed an in vivo distribution study in humans,
which confirmed the previously described pharmacokinetics (5).
Recent preliminary preclinical evaluation of 18F-FPEB has shown
promising results, but a thorough validation for preclinical use has
not been reported yet (6).
We report here on the preclinical characterization and quanti-
fication of 18F-FPEB in rat brain. As the primary objective, we
assessed the pharmacologic specificity of brain uptake and binding
characteristics of 18F-FPEB. As a second objective, we quantified
the imaging data by compartmental modeling and high-frequency
serial arterial measurements of both parent radiotracer and radio-
metabolites. Finally, simplified modeling method estimates were
evaluated to overcome the need for arterial sampling in this species.
MATERIALS AND METHODS
18F-FPEB Characteristics and Preparation
18F-FPEB was synthesized starting from the nitro-precursor using
microwave irradiation. A detailed description of the radiosynthesis
will be published elsewhere.
Animals
Experiments were conducted in 30 male Wistar rats (Janvier Labora-
tories) weighing on average 2816 18 g at the time of the experiments. All
animals were housed 2 or 3 to a cage in an average room temperature of
22C and a 12-h light–dark cycle with free access to food and water. The
research protocol was approved by the local Animal Ethics Committees of
the University of Leuven (P156/2013) and was performed in accordance
with European Ethics Committee guidelines (decree 86/609/EEC).
Small-Animal PET Imaging
Imaging experiments were performed on a lutetium oxyorthosilicate
detector-based small-animal tomograph (FOCUS-220; Siemens Medi-
cal Solutions USA), which has a transaxial resolution of 1.35 mm in full
width at half maximum. Data were acquired in a 128 · 128 · 95 matrix
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with a pixel width of 0.475 mm and a slice thickness of 0.796 mm.
The coincidence window width was set at 6 ns. During PET imaging,
rats were kept under gas anesthesia (2.5% isoflurane in oxygen at a
flow rate of 1.5 l/min), and their body temperature was maintained
between 36.5C and 37C with a heating pad. On average, 37.6 6
5.6 MBq (specific activity range, 35–150 GBq/mmol; mass dose
range, 1.03–5.64 mg) were injected into the tail vein using an in-
fusion needle set. Individual dynamic 180-min scans were started
simultaneously with the injection of 18F-FPEB to assess the kinetics
of 18F-FPEB using compartmental modeling (n 5 10) and for pre-
treatment evaluation (n 5 3).
For the pretreatment experiment, MTEP-hydrochloride (3-[(2-methyl-
1,3-thiazol-4-yl)ethynyl]pyridine hydrochloride; Sigma-Aldrich USA),
an mGluR5-negative allosteric modulator, was dissolved to a concentra-
tion of 20 mg/mL in distilled water. MTEP was administered intraper-
itoneally 15 min before and 40 and 95 min after 18F-FPEB injection. The
dose of 20 mg/mL and the time of treatments were based on previous
reports to ensure complete blocking of mGluR5 (7,8).
List-mode acquisition data were Fourier-rebinned in 33 frames (4 ·
15, 4 · 60, 5 · 180, 8 · 300, and 12 · 600 s). Sinograms were recon-
structed using an iterative maximum a posteriori probability algorithm
with ordered subsets (18 iterations, 9 subsets; fixed resolution, 1.5 mm)
(9). All scans were corrected by means of a 57Co-attenuation scan.
Measurement of 18F-FPEB in Plasma
To measure the concentration of 18F-FPEB in rat plasma, an arterial
cannula was placed in the femoral artery. After slow bolus injection of
18F-FPEB, arterial blood was continuously collected for 1 min (15
samples, ;1 sample every 4 s), followed by 100-mL samples at 90,
120, and 150 s and 200-mL samples at 3, 5, 10, 25, 40, 60, 120, and
180 min. All blood samples were immediately stored on ice to minimize
possible tracer metabolism. The plasma time–activity curves were cor-
rected for the fraction of unchanged radioligand using reversed-phase
high-performance liquid chromatography (HPLC) separation (LaChrom
Elite HPLC system [Hitachi]; Chromolith C18, 3 · 100 mm [Merck]).
Plasma samples were isolated from whole blood by centrifugation at
3,000 rpm for 5 min and spiked with authentic FPEB reference
(25 mL) before HPLC analysis. The HPLC separation was achieved with
gradient mixtures of 0.05 M sodium acetate (pH 5.5) (A) and CH3CN
(B) (1% B, flow rate 0.5 mL/min, from 0 to 4.1 min; 1% B, flow rate
1.0 mL/min, from 4.1 to 9 min; 90% B, flow rate 1.0 mL/min, from 9.0
to 12.0 min; 90% B, flow rate 0.5 mL/min, from 12.0 to 12.1 min; and
1% B, flow rate 0.5 mL/min, from 12.1 to 15.0 min). The HPLC eluate
was collected after passing through an inline ultraviolet detector (296 nm).
Collection was performed per minute, except for the period between 8
and 12 min at which samples were collected every 15 s. This period of
higher temporal resolution allowed better delineation of the parent tracer
and 1 of the radiometabolites. Radioactivity in all fractions was mea-
sured using an automated g-counter equipped with a 7.62-cm NaI(TI)
well crystal coupled to a multichannel analyzer (2480 Wizard; Wallac).
Results were corrected for background radiation, physical decay, and
counter dead time.
Measurement of 18F-FPEB Radiometabolites in Brain
For each time point, 2 rats were infused with approximately 37
MBq of 18F-FPEB under isoflurane anesthesia as described above. At
10, 30, 60, 120, and 180 min after injection, rats were euthanized
using a 180 mg/kg overdose of sodium pentobarbital (Nembutal; Ceva
Sante Animale) and perfused transcardially with saline. The brain was
carefully removed from the skull, after which the cerebrum and cer-
ebellum were separated. After homogenization, in 3 and 2 mL of
CH3CN, respectively, the supernatant was collected and filtered with
a Millex Syringe Filter (Merck Millipore). One mL of this filtrate was
diluted with 1 mL water after which 0.5 mL of this solution was
spiked with authentic FPEB reference and injected onto the HPLC
consisting of an analytic XBridge column (C18, 5 mM, 3 mm·100
mm; Waters) eluted with a mixture of 0.05 M sodium acetate (pH
5.5) and CH3CN (50/50 v/v) at a flow rate of 0.8 mL/min. HPLC
eluates were collected every minute after passing through an ultravi-
olet detector (296 nm). Radioactivity in the fractions was measured
using the automated g-counter.
In Vitro Rat Brain and Blood Stability Studies
Fresh rat blood, plasma, and homogenized perfused brain were
incubated with about 18 MBq of tracer at 37C. After 60 min of
incubation, samples were cooled on ice. Blood and brain homogenate
samples were processed and analyzed by reversed-phase HPLC as
described above.
Small-Animal PET Analysis
PET images were normalized to a custom-made rat brain template
in Paxinos stereotactic space, allowing the use of a predefined volume-
of-interest map. The procedure for spatial normalization and its
validation have been described previously by our group (10). Time–
activity curves were generated for the bilateral caudate/putamen,
nucleus accumbens, hippocampus, cortex, and cerebellum of each in-
dividual scan using PMOD software (version 3.6; PMOD Technolo-
gies). The macrostructures that were used were based on the spatial
resolution of the FOCUS-220 system (11). The radioactivity concen-
tration in each brain region was normalized to the injected dose and
body weight and expressed as standardized uptake value. Receptor
occupancy was calculated with the Michaelis–Menten equation (12),
using the free fraction of 18F-FPEB determined in humans (13).
Compartmental Modeling of 18F-FPEB
in Rat Brain
All 18F-FPEB input curves were obtained af-
ter correction for 18F decay and radiometabolite
correction, which was based on a hill-function
fitting of the radiometabolites. One-tissue-
compartment and 2-tissue-compartment models
(2TCM) were considered to describe 18F-FPEB
kinetics in the rat brain using the metabolite-
corrected plasma input function. Fittings were
obtained for different scan durations and evalu-
ated both by visual assessment and by model
selection criterion values. Distribution volume
(VT) and nondisplaceable binding (BPND) were
used as outcome parameters. BPND was calcu-
lated as VT/VRef – 1, where VRef is the distribu-
tion volume of the reference region.
FIGURE 1. (A) Intact percentage of 18F-FPEB over time in cerebrum homogenate (n) and plasma
(●). B) Reconstructed chromatograms showing intact tracer in plasma eluting at 10 min. Two
polar radiometabolites eluting at 3 and 9 min were observed.
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To determine the time-stability of the tracer and the minimum
scanning time necessary to obtain reliable estimates for BPND, we ana-
lyzed PET data from each rat after removing variable durations of the
terminal portion of the scans. We analyzed data of all animals for the
periods between 0–30, 60, 90, 120, and 180 min. Estimates of BPND
were compared with the reference value obtained with the best-fitting
dataset. The solution was considered acceptable if the result was within
10% of that from the analysis of the reference value.
Simplification of 18F-FPEB Quantification
Because arterial blood sampling in rats is technically demanding
and a terminal procedure, it hampers serial small-animal PET studies
in this species. Therefore, we also explored the possibility of simplifying
18F-FPEB quantification in rat studies. For this purpose, the simplified
reference tissue model (SRTM), Logan noninvasive (NI), and Ichise’s
original multi-linear reference tissue model (MRTMO) were tested as
reference models with BPND as the outcome parameter. Reference
models were compared with the best-fitting compartmental model.
Test–Retest Variability
Six animals were scanned twice for 120 min with a 1-wk interval
to evaluate the (short-term) interscan variation between different
scans of the same animal. The intraclass correlation coefficient
(ICC) was used to assess within-subject variability relative to the
between-subject variability. Additionally, percentage difference
was also calculated as the difference between test and retest
values on the same subject divided by their average, that is, (Y1 – Y2)/
((Y1 1 Y2)/2).
Statistical Analysis
The reported values are mean 6 SD. Conventional statistics were
performed using GraphPad Prism (version 5.0; GraphPad Software).
This includes reported biases, which are obtained with the Bland–
Altman method. ICCs were calculated with SPSS 22 (IBM Corp.)
for absolute agreement in a 2-way mixed model on individual mea-
surements. Significance was defined at the 95% probability level.
RESULTS
Plasma Kinetics
The percentage of intact 18F-FPEB in arterial plasma over time
is shown in Figure 1A. At 3 min after injection, 68% 6 7% of the
total radioactivity in arterial plasma corresponded to intact 18F-
FPEB. This fraction declined to 44% 6 9% at 10 min, 26% 6 6%
at 40 min, 19% 6 5% at 60 min, 16% 6 5% at 120 min, and
11% 6 3% at 180 min after tracer injection. In rat plasma, 2 radio-
metabolites were observed, which eluted earlier (at 3 and 9 min)
than 18F-FPEB (Rt 5 10 min) on the HPLC and are therefore more
hydrophilic (polar) than the parent radioligand (Fig. 1B). No
radiometabolites with higher lipophilicity than 18F-FPEB were
detected.
In Vitro and Ex Vivo Radiometabolite Analysis in Rats
18F-FPEB was shown to be metabolically stable in rat whole
blood, rat plasma, and rat brain homogenates in vitro as the
fraction of radiometabolites observed after 60 min incubation
at 37C was less than 2%. To assess whether 18F-FPEB radio-
metabolites are also present in the in vivo brain, 2 rats were
sacrificed at 10, 30, 60, 120, and 180 min after 18F-FPEB in-
jection. Polar radiometabolites were present in the cerebrum
after 60 min but never accounted for more than 5% of the total
radioactivity in the samples (Fig. 1A). Low amounts of radio-
metabolites (,6.5%) were present in the cerebellum. However,
the total radioactivity in the cerebellum never exceeded 1.5% of
the cerebrum.
Brain Kinetics
After injection of 18F-FPEB, all rats
showed radioactivity in the brain in a pat-
tern consistent with the distribution of
mGluR5, that is, highest concentrations
in the caudate/putamen, nucleus accum-
bens, and hippocampus and low con-
centrations in both cerebellum and brain
stem (Fig. 2A) (14). 18F-FPEB uptake
in receptor-rich regions increased to a
peak around 25 min, after which a slow and
approximately linear decline was observed
toward 25% of the maximal amplitude at 3 h
(Fig. 2B). Receptor occupancy calculation
confirmed that occupancies in all studies
remained below 1.3% and thus well be-
low the pharmacologic threshold and in
the range of microdosing.
FIGURE 2. (A) Representative small-animal PET image of rat brain after
18F-FPEB injection averaged from 10 to 60 min. (B) Averaged time–
activity curves after venous injection of 18F-FPEB for (from high to low)
striatum (●), nucleus accumbens (▲), hippocampus (▼), cortex (○), thal-
amus (♦), and cerebellum (n). Error bars represent 1 SD. SUV 5 stan-
dardized uptake value.
FIGURE 3. (A) Time–activity curves expressed in standardized uptake value (SUV) after pre-
treatment with MTEP for same regions as shown in Figure 2. (B) Results of blocking with MTEP
(20 mg/kg) in comparison with baseline VT as obtained with 2TCM. Hippo 5 hippocampus;
NAC 5 nucleus accumbens.
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Specificity and Binding Characteristics of 18F-FPEB in Rats
18F-FPEB was selective for the mGluR5 in rats as assessed by
pharmacologic pretreatment with the highly selective mGluR5-
negative allosteric modulator MTEP (15). Full blockage was
obtained by injecting MTEP (20 mg/kg) every 55 min, starting
15 min before the injection of 18F-FPEB. The ratio of the area
under the curve between receptor-rich and reference region
time–activity curves (e.g., striatum/cerebellum) decreased from
110 to 1.10 (Fig. 3). On the basis of these results, the cerebellum
is used as the reference region for the following kinetic modeling
analyses.
Compartmental Modeling of 18F-FPEB in Rat Brain
2TC modeling showed to be superior to the 1-tissue-compartmental
model, with both better visual fit and higher model selection
criterion values. Both criteria were optimal for the scan
duration of 120 min. The VT values obtained with the 2TCM
were high for both striatum (41.2 6 7.7) and the nucleus
accumbens (37.3 6 6.9), intermediate for both hippocampus
(32.4 6 5.6) and cortex (26.9 6 4.6), with lower values for
the thalamus (16.2 6 3.5). Time-stability analysis of 2TCM
VT in cerebral regions, for example, the thalamus, showed pos-
itive bias compared with the 120-min reference for 30 min
(10% 6 25%), 60 min (9% 6 14%), 90 min (4% 6 19%), and
180 min (5% 6 14%) (Fig. 4A).
Simplification of 18F-FPEB Quantification
Binding potentials obtained with the 2TCM are closely approx-
imated by the evaluated reference models (Table 1). Of the latter, a
clear reduction in variance can be observed for values obtained
with SRTM and MRTMO. SRTM and MRTMO underestimated the
2TCM BPND (21.1% 6 13.7% and 20.7% 6 13.7%, respec-
tively), whereas Logan NI had a 2.0% 6 13.9% overestimation
as compared with the 2TCM BPND values.
For SRTM and MRTMO this bias remained stable for the shorter
time frames of 90- (2.0 and 2.2%, respectively), 60- (5.85 and
5.3%), and 30-min (2.9 and 20.3%) scan durations. Logan NI
however, showed an increasing overestimation ranging from
2.6% at 90 min to 20.8% at 30 min. All 3 methods showed a
relatively large underestimation for 180-min scan duration as com-
pared with 120 min (SRTM,27.2%; MRTMO,29.6%; and Logan
NI, 217.2%) (Fig. 4).
Test–Retest Variability
High repeatability was found for every reference method in all
time frames (Table 2). However, the highest repeatability was
found for a scan duration of 30 min for SRTM (ICC 5 0.92)
and MRTMO (ICC 5 0.93), whereas the highest values for Logan
NI were found for 60-min scan durations (ICC 5 0.88). This high
repeatability was also reflected in the average test–retest values
of all regions studied with minimal differences at 60 min for
MRTMO (22.3% 6 14.9%) and Logan NI (21.0% 6 15.3%)
and at 30 min for SRTM (22.7% 6 12.6%).
DISCUSSION
The evaluation of 18F-FPEB in rats demonstrated uptake in the
brain consistent with the known distribution of mGluR5 (16,17).
Binding was almost 100% specific. Two polar radiometabolites
were present in plasma, but these did not enter the brain. BPND
values obtained with 2TC modeling in combination with arterial
sampling corresponded excellently with values obtained with sim-
plified reference methods, that is, SRTM, MRTMO, and Logan NI.
Test–retest scan analysis showed high consistency and low inter-
scan variation with 18F-FPEB.
Plasma radiometabolite analysis showed a rapid conversion of
parent to polar radiometabolites contributing to 46% and 89% of
the radioactivity at 10 and 180 min, respectively. This pattern is
similar to the one reported in humans by Wong et al. but slower
than in monkeys (5,18). The detection of only 1 polar radiometa-
bolite by Hamill et al., however, could suggest that the radiome-
tabolite eluting directly before the parent fraction (Fig. 1B) might
have been missed.
FIGURE 4. Bias, as compared with 120-min 2TCM, with confidence
band (±SD) for VT obtained with 2TCM (A) and for BPND obtained with
MRTMO (B), SRTM (C), and Logan NI (D) for scan durations of 30, 60, 90,
120, and 180 min. For 2TCM, 120-min time point is omitted as this is
used as reference and therefore by definition zero.
TABLE 1
Binding Potentials Obtained with Both Plasma-Corrected 2TCM and 3 Simplified Reference Models for 120-Minute Data
Brain region 2TC SRTM MRTMO Logan NI
Striatum 11.36 ± 1.66 11.33 ± 0.99 11.30 ± 1.02 11.12 ± 1.23
Nucleus accumbens 10.29 ± 2.05 9.99 ± 1.33 9.95 ± 1.36 9.81 ± 1.51
Hippocampus 8.76 ± 1.32 8.81 ± 0.78 8.79 ± 0.80 8.64 ± 0.98
Cortex 7.10 ± 1.0 7.21 ± 0.60 7.20 ± 0.62 7.06 ± 0.77
Thalamus 3.88 ± 0.91 4.28 ± 0.55 4.22 ± 0.55 4.0 ± 0.65
Data are mean ± SD.
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The in vitro evaluation of 18F-FPEB in rats showed no radio-
metabolite formation in plasma, blood, or brain homogenates.
These findings are also in agreement with data from Hamill et al.
showing metabolism of 18F-FPEB in vitro only after addition
of liver microsomes (19). Our study is the first to show that there
is no significant ex vivo radiometabolite presence in the cerebrum
up to 180 min after injection for the 18F-FPEB radiotracer. Al-
though the cerebellum showed minor radiometabolite presence
(,6.5%), the total absolute activity in the cerebellum was low (only
1.5% when compared with the cerebrum). This observation could
be explained by incomplete washout of radioactivity in the circula-
tory system, which can be seen with saline perfusion (20). Quan-
tification of the mGluR5 using 18F-FPEB is thus feasible when
relying on the radiometabolite-corrected ligand input function only.
The in vivo evaluation of 18F-FPEB in rats demonstrated uptake
in the brain in a pattern consistent with the known mGluR5 dis-
tribution pattern of both ex vivo (14) and in vivo (21) data. Tracer
binding was shown to be reversible with favorable kinetics allowing
accurate quantification with scan durations of minimally 60 min.
Moreover, low intersubject variability (Table 2) allows sensitive
comparison between individuals and groups.
Scans obtained after the administration of MTEP showed a
decrease in signal from receptor-rich regions to the same level of
the reference region, that is, the cerebellum, thus confirming the
high specificity of 18F-FPEB (Fig. 3) (17,22). A similar trend was
reported for another mGluR5 tracer, 11C-ABP688, in rats. How-
ever, for this tracer no full blockage was achieved (22). This can
either be explained by the use of MPEP, which has a lower affinity
and specificity than MTEP, or by a lower specificity of this tracer
compared with 18F-FPEB (7).
Modeling showed that a 1-tissue-compartment model was
unable to fit the data, but a 2TCM provided good fits in all
regions. When different scan durations were considered, best
results were obtained with scan data of 120 min according to both
visual assessment and model selection criterion values. The 2TCM
has also been reported appropriate for 11C-ABP688 in rats by
Elmenhorst et al. who also showed that the cerebellum can
be used as a reference region for mGluR5 PET imaging (22).
However, their approximation with reference tissue models of
the values obtained with the 2TCM is evaluated only by correla-
tion analysis and is therefore hard to interpret (23). Although the
ordering of regions according to BPND values (e.g., striatum highest,
cerebellum lowest) is the same as for 11C-ABP688, absolute BPND
values are not. Indeed, BPND values found, both with 2TCM and
with reference tissue models, for 18F-FPEB are on average 4–5
times higher. This could theoretically be explained by a difference
in receptor density between the 2 scanned populations but is more
likely a result of the higher affinity of 18F-FPEB for mGluR5
(dissociation constant, 0.05 nmol/L vs. 1.7 nmol/L) (4,24). Indeed,
the binding potentials reported in this article are in concordance
with previously reported values for 18F-FPEB in rats (6).
To avoid cumbersome arterial sampling in future animal model
scans, the results of the 2TCM for 120 min were compared with
SRTM, MRTMO, and Logan NI. Minimal bias was obtained with
SRTM and MRTMO for 120-min data frames (21.1 6 13.7% and
20.76 13.7, respectively). Furthermore, this bias remained stable
and below 6% for 30, 60, and 90 min with both methods (Fig. 4).
High ICCs were obtained for these time frames with test–retest
scans using SRTM and MRTMO (Table 2). This consistency be-
tween scans was also confirmed by the small bias on both all
regions combined (,3.0%) and individual regions (,5%). These
results are similar to the ones obtained for 11C-ABP688 in rats
(25).
Mild defluorination is observed in the later time frames by the
appearance of bone structures on the PET images. The influence of
bone uptake was negligible in receptor-positive regions but was
noticeable in the reference region directly adjacent to bone.
Therefore, the reference region used in this study was delineated
within the cerebellum thus evading spill-in from bone structures.
Additionally, this influence might be more pronounced in late time
frames, when radioactivity concentrations in the brain have
decreased. Indeed, Kang et al. reported the absence of bone
uptake in their 90-min scans (6), which could explain the less
optimal fit of the 2TCM for the 180-min data as compared with the
120-min scans. Interestingly, after MTEP administration no bone
uptake of radioactivity was present on PET images. HPLC analy-
sis of plasma after MTEP administration also showed absence of
the most polar radiometabolite. This probably means that this
metabolite, likely formed by defluorination at the fluorophenyl
ring of 18F-FPEB, is a product of an enzymatic pathway, which
is at least partly shared with MTEP.
CONCLUSION
We have shown that 18F-FPEB is a suitable radioligand for the in
vivo visualization and quantification of mGluR5 in rats. Because of
the highly specific signal and low intersubject variability, it provides
a sensitive tool for preclinical research on mGluR5-related topics.
The presence of a valid reference region allows reliable and accu-
rate simplified quantification using SRTM and MRTMO. Moreover,
TABLE 2
ICC and Percentage Difference Values for All Regions of Test–Retest Scans Using SRTM, MRTMO, and Logan NI for
Different Scan Durations
SRTM MRTMO Logan NI
Scan duration ICC PD ICC PD ICC PD
120 0.80 −6.7 ± 18.6 0.78 −7.6 ± 19.4 0.70 −11.8 ± 23.4
90 0.85 −3.9 ± 16.2 0.84 −3.5 ± 17.1 0.81 −3.6 ± 18.7
60 0.88 −3.4 ± 14.4 0.88 −2.4 ± 14.9 0.88 −1.0 ± 15.3
30 0.92 −2.7 ± 12.6 0.93 −3.0 ± 11.4 0.86 −6.0 ± 15.9
PD (percentage difference) data are mean ± SD.
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test–retest ICC scores of greater than 0.88% for 30- and 60-min
scans allow for high-throughput and longitudinal experimental de-
signs. Our data suggest that optimal results with 18F-FPEB can be
obtained with SRTM and MRTMO for scans of 60 min.
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